VIKIA Rota-Adeno is a rapid, qualitative, chromatographic immunoassay which simultaneously detects rotaviruses and adenoviruses in stool specimens. Rotaviruses and adenoviruses are responsible for,th
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens.
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis.
ELISA for Anti-Proteinase 3 PR3 (cANCA).
Medicine Products:(Date:12/3/2008)...,000 to Burnham Institute for Medical Research (Bu... The funding, part of HeadNorth,s Chronic Spinal C...an Snyder, Stem Cell Program Director at Burnham a... Repair at the University of California, San Diego...njuries. , "One of the main hopes of the spinal ...
(Date:12/3/2008)...e-USNewswire/ -- The nationally recognized Consum...the health insurance industry,s self-serving plan ...k insurance policies or face tax penalties or othe...n charge or reduce health insurance profit and ove...are spending. As a candidate, President-elect Obam...
(Date:12/3/2008)...s J. Serbaroli has joined the international law fi... office as a shareholder in the Health and FDA Bu...Traurig from Cadwalader, Wickersham & Taft LLP...tate Public Health Council for more than 13 years....s of industry experience, will expand Greenberg Tr...
(Date:12/3/2008)...Great, a MED3OOO company that,delivers EHR techno...y,clinics, recently entered into a 14-year Applic...HealthCare Alliance to provide electronic medical ... , The WVVA Healthcare Alliance is made up ...in the Alleghany Highlands of Virginia and the Gre...
Breaking Medicine News(10 mins):Health News:Burnham and HeadNorth Foundation join forces to advance spinal cord research 2Health News:Consumer Watchdog Urges President-elect Obama to Continue to Oppose Mandatory Purchase of Junk Health Insurance 2Health News:Consumer Watchdog Urges President-elect Obama to Continue to Oppose Mandatory Purchase of Junk Health Insurance 3Health News:Greenberg Traurig's New York Office Expands Health Care Practice With Addition of Francis Serbaroli 2Health News:Greenberg Traurig's New York Office Expands Health Care Practice With Addition of Francis Serbaroli 3Health News:WVVA HealthCare Alliance Signs 14-Year ASP EHR Agreement 2Health News:WVVA HealthCare Alliance Signs 14-Year ASP EHR Agreement 3Health News:WVVA HealthCare Alliance Signs 14-Year ASP EHR Agreement 4(Date:12/1/2008)...ENB-0040 at Children,s Hospital, Health Sciences C...ewswire/ -- Enobia Pharma, an emerging Canadian bi...tics for serious bone disorders, today announced t...am for hypophosphatasia was dosed. Enobia is inves...-0040 for the treatment of this rare and often cri...
(Date:12/1/2008)...stCall/ -- Genaera Corporation (Nasdaq: GENR ) ...in study MSI-1436C-102 (Study 102), the multiple a...-1436) in overweight and obese type 2 diabetics. M...f type 2 diabetes and obesity which works centrall...pathways through the highly selective inhibition o...
(Date:12/1/2008)...Vax Labs, Inc.,(OTC Bulletin Board: GOVX), an Atl... vaccines for diseases caused by HIV-1 (Human Immu...announced today that the launch of its Phase 2a Hu...s across North and South America.,These trials ar...titutes of,Health (NIH), and the HIV Vaccine Tria...
(Date:11/30/2008)...normalities in auditory and language processing ma...sorder by using magnetoencephalography (MEG), acco...ting of the Radiological Society of North America ...iny magnetic fields associated with electrical bra...air of research in the Department of Radiology at ...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Dole Invites Consumers to Show Their Wild Side 21 1614 1Dole Invites Consumers to Show Their Wild Side 21 1614 2Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 697 1Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 697 2NASA celebrates a decade observing climate impacts on health of worlds oceans 461 1NASA celebrates a decade observing climate impacts on health of worlds oceans 461 2NASA celebrates a decade observing climate impacts on health of worlds oceans 461 3Planetary geoscience paleontology and more at GSA Annual Meeting in Denver next month 460 1Planetary geoscience paleontology and more at GSA Annual Meeting in Denver next month 460 2Planetary geoscience paleontology and more at GSA Annual Meeting in Denver next month 460 3Planetary geoscience paleontology and more at GSA Annual Meeting in Denver next month 460 4Planetary geoscience paleontology and more at GSA Annual Meeting in Denver next month 460 5...Findings Show Survival Improvement with Lower Dose... REVLIMID and other,Drugs in Newly Diagnosed Myelo...ewswire/ -- The,International Myeloma Foundation (..., advocacy and support for myeloma patients,famil...cians should,consider lowering the dose of the ste...
...LANTA--(BUSINESS WIRE)--Apr 5, 2007 - MIV Therapeu...per of next-generation,biocompatible coatings and ...stents and other implantable medical devices, toda...test confirmed that,merging Biosync Scientific,s c...ently acquired, with the Company,s polymer-free dr...
Other Medicine Technology:The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients 2The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4